GL-V9 synergizes with oxaliplatin of colorectal cancer via Wee1 degradation mediated by HSP90 inhibition
Journal of Pharmacy and Pharmacology · 2024
DOI: 10.1093/jpp/rgae060 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2024. Verfasst von Hongyu Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing 210009…. Hauptthemen laut MEDLINE: Oxaliplatin, Cell Cycle Proteins, Colorectal Neoplasms, Protein-Tyrosine Kinases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Objectives
GL-V9 exhibited anti-tumour effects on various types of tumours. This study aimed to verify if GL-V9 synergized with oxaliplatin in suppressing colorectal cancer (CRC) and to explore the synergistic mechanism.
Methods
The synergy effect was tested by MTT assays and the mechanism was examined by comet assay, western blotting and immunohistochemistry (IHC). Xenograft model was constructed to substantiated the synergy effect and its mechanism in vivo.
Results
GL-V9 was verified to enhance the DNA damage effect of oxaliplatin, so as to synergistically suppress colon cancer cells in vitro and in vivo. In HCT-116 cells, GL-V9 accelerated the degradation of Wee1 and induced the abrogation of cell cycle arrest and mis-entry into mitosis, bypassing the DNA damage response caused by oxaliplatin. Our findings suggested that GL-V9 binding to HSP90 was responsible for the degradation of Wee1 and the vulnerability of colon cancer cells to oxaliplatin. Functionally, overexpression of either HSP90 or WEE1 annulled the synergistic effect of GL-V9 and oxaliplatin.
Conclusions
Collectively, our findings revealed that GL-V9 synergized with oxaliplatin to suppress CRC and displayed a promising strategy to improve the efficacy of oxaliplatin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing 210009, People's Republic of China.
- Department of Hematology, Zhongda Hospital, School of Medicine, Southeast University, Institute of Hematology Southeast University, Nanjing 210009, People's Republic of China.
- Department of General Thoractic Surgery, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210009, People's Republic of China.
ORCID-Profile: Hui Hui
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Chen, H., Yang, F., Zhao, Q., Wang, H., Zhu, M., Li, H., Ge, Z., Zhang, S., Guo, Q., & Hui, H. (2024). GL-V9 synergizes with oxaliplatin of colorectal cancer via Wee1 degradation mediated by HSP90 inhibition. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgae060
Vancouver
Chen H, Yang F, Zhao Q, Wang H, Zhu M, Li H, et al. GL-V9 synergizes with oxaliplatin of colorectal cancer via Wee1 degradation mediated by HSP90 inhibition. Journal of Pharmacy and Pharmacology. 2024. doi:10.1093/jpp/rgae060
BibTeX
@article{Chen2024,
author = {Chen, Hongyu and Yang, Fan and Zhao, Qianying and Wang, Hongzheng and Zhu, Mengyuan and Li, Hui and Ge, Zheng and Zhang, Shuai and Guo, Qinglong and Hui, Hui},
title = {GL-V9 synergizes with oxaliplatin of colorectal cancer via Wee1 degradation mediated by HSP90 inhibition},
journal = {Journal of Pharmacy and Pharmacology},
year = {2024},
doi = {10.1093/jpp/rgae060}
}
EUVIMED